Replies to post #78666 on Biotech Values

[spartex]

CELG Hep C drug -- you may be right that it is a reporting error. I'm not following CELG closely, but have owned DNDN and REGN for a while.

[DewDiligence]

What presence does CELG have in hepatitis C treatments, either approved or under development? I'm not aware of any so I assume this is an error.

That’s correct. Jay Markowitz (the biotech analyst from T. Rowe Price who was quoted in the Business Week article) must have misread GlobeImmune’s 5/15/09 PR and concluded that CELG would be developing GI-5005 for HCV. What confused him was presumably this paragraph about 1/3 of the way down:

http://finance.yahoo.com/news/GlobeImmune-and-Celgene-iw-15255937.html

Tarmogen® candidates are also being studied in Phase II clinical trials targeting hepatitis C.

A little knowledge is a dangerous thing.